Lung Cancer and bisphosphonate bone therapies-

Share Button

One of the strengths of PeopleBeatingCancer is that we take a wide view of cancer research and management. I first became aware of the critical importance of bone health when I was first diagnosed with multiple myeloma in 2/94.

My single plasmacytoma (early mm) had eaten through my fifth cervical vertebra- a real pain in the neck. Sorry…

I began bone strengthening therapy almost immediately.  Bone health remains a priority for me to this day (5/18/15).

Bone strengthening therapy is standard-of-care for mmers. And as far as I can see from my perspective as a cancer blogger, bone therapy should be a priority for ALL cancer patients. As early in the process as possible.

Since learning about the importance of bone health as a myeloma patient I have learned about bone health for many cancers. The study below talks about “skeletal-related events” in lung cancer but there are similar articles and studies on PBC citing the importance of bone health in myeloma, breast and prostate cancers as well.

To learn more about managing bone health for cancer patients and survivors, scroll down the page, post a question or comment and I will reply ASAP.

Thank you,

David Emerson

Long-term cancer survivor, creator, director PeopleBeatingCancer

Bone-targeted agents in the treatment of lung cancer

Over a third of patients with lung cancer will develop bone metastases during the course of their disease, resulting in symptoms of pain and immobility, and skeletal-related events (SREs) such as fracture, hypercalcaemia, surgery or radiotherapy to bones, and malignant spinal cord compression.

These reduce quality of life and increase mortality.

Preclinical research has identified the interactions between tumour cells and bone that are key to tumour cell survival and associated osteolysis. These data have led to the development of drugs to prevent osteoclast-mediated bone breakdown, such as zoledronic acid and denosumab, which are now licensed for use in patients with bone metastases from solid tumours. Both zoledronic acid and denosumab reduce the risk of SREs and increase time to first SRE, with minimal side effects.

In addition, denosumab improved survival in patients with lung cancer compared with zoledronic acid. Ongoing trials are testing whether these drugs can prevent the development of bone metastases from lung cancer. New bone-targeted agents showing promise in breast and prostate cancer include radium-223, cabozantinib and Src inhibitors. These agents require further evaluation in patients with lung cancer.

Posted in Newly Diagnosed, non-conventional therapies, side effects ID and prevention Tagged with:

Leave a Reply

Your email address will not be published. Required fields are marked *